Sunday, May 3, 2026

Suboxone and Talc Drive Weekly Federal Docket Surge as Nigh Goldenberg Initiates 150+ Filings

Pharmaceutical mass torts dominated the weekly federal docket, with the Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation absorbing 165 new complaints—driven almost entirely by a 159-case wave from Nigh Goldenberg Raso Vaughn PLLC. The Johnson & Johnson Talcum Powder Products Marketing, Sales Practices and Products Liability Litigation followed closely with 125 filings, anchored by 73 new suits from Napoli Shkolnik. Beyond legacy dockets, the rideshare sector maintained aggressive momentum, as the Uber Technologies, Inc., Passenger Sexual Assault Litigation captured 52 new filings over the past week. In parallel, the newly centralized Lyft Passenger Sex Assault Litigation (MDL 3171) has officially begun consolidating complaints before Judge Rita F. Lin in the Northern District of California, signaling a synchronized plaintiff posture against both industry giants.

Judge Seeborg Signals Intent to Appoint Settlement Master in Roblox Child Exploitation MDL

Federal proceedings in the Roblox Child Sexual Exploitation/Asault Litigation (MDL 3166) are pivoting toward resolution frameworks, with Chief Judge Richard Seeborg recently signaling his intent to appoint former U.S. Associate Attorney General Thomas J. Perrelli as a special settlement master. The judicial move, actively requested by plaintiffs' leadership, comes as the Northern District of California docket expands to roughly 150 pending actions (148 per JPML's May 1 report, plus ~2 new filings tracked since) alleging the gaming platform enabled child grooming through weak moderation and an unregulated pipeline to Discord. The appointment of a high-profile settlement master at this relatively early stage reflects significant pressure to address the systemic safety claims efficiently. For the defense, early mediation may prove crucial to avoiding a sprawling, highly publicized discovery battle involving minor plaintiffs' deeply sensitive data.

GLP-1 NAION Litigation Sets Critical June 'Science Day' Before Judge Marston

The Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Products Liability Litigation (MDL 3163) is advancing rapidly toward a pivotal June 2, 2026 Science Day hearing before Judge Karen S. Marston in the Eastern District of Pennsylvania. Centralized to handle allegations that Ozempic, Wegovy, and related drugs cause a condition leading to permanent blindness, the docket has now grown to roughly 93 pending actions (86 per JPML's May 1 report, plus ~7 new filings tracked since). Plaintiffs are expected to rely heavily on recent European regulatory actions to establish general causation. Specifically, counsel will likely highlight the European Medicines Agency's classification of NAION as a semaglutide side effect and the UK MHRA's urgent safety update, raising the scientific stakes for Novo Nordisk and Eli Lilly ahead of formal Daubert motion practice.